iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations

NCT ID: NCT03728322

Last Updated: 2018-11-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-31
• Study Completion Date: 2021-01-31

Brief Summary

This is a single centre、single arm、open-label study，to investigate the safety and efficacy of the gene correction of HBB in patient-specific iHSCs using CRISPR/Cas9.

Detailed Description

The purpose of this study is to evaluate the efficacy and safety of transplantation iHSCs intervent subjests with β-thalassemia mutations.

Conditions

Thalassemia

Study Design

• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

iHSCs treatment group

Group Type: EXPERIMENTAL

iHSCs treatment group

Intervention Type: BIOLOGICAL

iHSCs intravenous injection

Interventions

iHSCs treatment group

iHSCs intravenous injection

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Subjects ≥ 2 and ≤ 60 years of age

2. Subjects was confirmed the transfusion-dependent β-thalassemia

3. Adequate organ function, as defined by:

Serum creatinine ≤ 1.5 mg/dl ； Serum ALT/AST）≤2.5×ULN；ALB≥25g/L； Serum total bilirubin < 1.5x ULN Left ventricular ejection fraction≥50%

4. Chest X-ray and ecg test results were normal, no serious cardiopulmonary diseases

5. Subjects survival was expected≥6 months

6. Adult patients were willing to use reliable contraceptives (such as condoms) and not to donate sperm throughout the study period and within three months of discharge

7. Subjects and the guardians able to undergo post-physical therapy/rehabilitation

Exclusion Criteria

1. Subjects allergic to macromolecular biological agents such as antibodies or cytokines

2. Subjects receipt of any investigational clinical trials within 3 months.

3. Subjects previous treatment with any hematopoietic stem cell transplantation or other organ transplantation

4. Uncontrolled bleeding symptoms

5. Severe cardiovascular disease is known, including any of the following:

Myocardial infarction or thrombosis has occurred in the past six months Subjects with unstable angina pectoris Subjects with Class III/IV cardiovascular disability according to the New York Heart Association Classification

6. Subjects have one kinds of tumors within 5 years

7. Active hepatitis B (HBV DNA>1000copy/mL), hepatitis C or HIV infection.

8. Subjects have an infectious diseases that cannot be controlled within 4 weeks

9. subjects have severe central nervous system disease or epilepsy

10. Subjects are Suffering from mental illness; Patients with alcohol dependence, drug abuse, drug addiction, and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results

11. Women in pregnancy (positive urine/blood pregnancy test) or lactation

12. Subjects who have other conditions that were not appropriate for the group determined by the researchers.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allife Medical Science and Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

HBB HSC-01

Identifier Type: -

Identifier Source: org_study_id